Skip Ribbon Commands
Skip to main content
Navigate Up
Sign In
 
 

 Latest News

 
7/2/2015
The study presents a cost-effective treatment option for patients with chronic genotype 1 HCV infection
7/2/2015
​A systematic literature review was conducted to provide an overview of published literature in the last 10-years.
7/2/2015
The model allows patients to move through a treatment sequence with treatment response measured via ACR criteria
4/14/2015
ISPOR and Value in Health, journal for research that advance the field of pharmacogenomics and outcomes research, endorse Pharmerit’s academic research on reimbursement in Scotland.
4/10/2015
Type 2 diabetes mellitus is estimated to account for 7–12% of the UK National Health Service expenditure. Economic analysis is critical to ensuring that limited resources are used effectively.
3/9/2015
Analysis demonstrates the sublingual native 5-grass tablet to be cost-effective relative to a mix of subcutaneous allergoid compounds
3/3/2015
Pharmerit Europe has a new management team of Bram Verheggen, Maarten Treur, and Stephanie Stephens. Together they are responsible for all aspects of Pharmerit Europe, but each has their own key focus.
1/6/2015
Pharmerit conducted an analysis to estimate the incremental cost-effectiveness of hexaminolevulinate for patients diagnosed with non-muscle invasive bladder cancer (NMIBC) in Italy
12/15/2014
Despite its rarity, anal cancer places a significant economic burden on the public purse and moreover resource pressures on the national health service.
11/19/2014
We have enjoyed meeting you at the 17th European ISPOR conference in Amsterdam, November 2014. Hand-outs of the poster sessions are available on our ISPOR Amsterdam event page.
Contact Feel free to contact us if you have any questions